While RAF265 showed a relatively low response rate and some significant and prolonged toxicities (particularly thrombocytopenia and visual problems) making its therapeutic index suboptimal for further pursuit, attempting to selectively target mutant BRAF proved to be a sound strategy as evident by the activity observed with more selective BRAF inhibitors such as vemurafenib and dabrafenib in this patient population. This evidence concerns the gene BRAF and Thrombocytopenia.